193 related articles for article (PubMed ID: 24747751)
1. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.
Matsui H; Masaki T; Akinaga Y; Kiba A; Takatsu Y; Nakata D; Tanaka A; Ban J; Matsumoto S; Kumano S; Suzuki A; Ikeda Y; Yamaguchi M; Watanabe T; Ohtaki T; Kusaka M
Eur J Pharmacol; 2014 Jul; 735():77-85. PubMed ID: 24747751
[TBL] [Abstract][Full Text] [Related]
2. Chronic administration of the metastin/kisspeptin analog KISS1-305 or the investigational agent TAK-448 suppresses hypothalamic pituitary gonadal function and depletes plasma testosterone in adult male rats.
Matsui H; Tanaka A; Yokoyama K; Takatsu Y; Ishikawa K; Asami T; Nishizawa N; Suzuki A; Kumano S; Terada M; Kusaka M; Kitada C; Ohtaki T
Endocrinology; 2012 Nov; 153(11):5297-308. PubMed ID: 23027808
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel investigational nonapeptide KISS1R agonists with testosterone-suppressive activity.
Asami T; Nishizawa N; Matsui H; Nishibori K; Ishibashi Y; Horikoshi Y; Nakayama M; Matsumoto S; Tarui N; Yamaguchi M; Matsumoto H; Ohtaki T; Kitada C
J Med Chem; 2013 Nov; 56(21):8298-307. PubMed ID: 24047141
[TBL] [Abstract][Full Text] [Related]
4. Design and Synthesis of an Investigational Nonapeptide KISS1 Receptor (KISS1R) Agonist, Ac-d-Tyr-Hydroxyproline (Hyp)-Asn-Thr-Phe-azaGly-Leu-Arg(Me)-Trp-NH
Nishizawa N; Takatsu Y; Kumano S; Kiba A; Ban J; Tsutsumi S; Matsui H; Matsumoto SI; Yamaguchi M; Ikeda Y; Kusaka M; Ohtaki T; Itoh F; Asami T
J Med Chem; 2016 Oct; 59(19):8804-8811. PubMed ID: 27589480
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of pharmacokinetics/pharmacodynamics and efficacy of one-month depots of TAK-448 and TAK-683, investigational kisspeptin analogs, in male rats and an androgen-dependent prostate cancer model.
Tanaka A; Nakata D; Masaki T; Kusaka M; Watanabe T; Matsui H
Eur J Pharmacol; 2018 Mar; 822():138-146. PubMed ID: 29355559
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of pharmacokinetic/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitive prostate cancer model.
Ishikawa K; Tanaka A; Kogame A; Watanabe T; Tagawa Y; Matsui H
Eur J Pharmacol; 2018 Jun; 828():126-134. PubMed ID: 29580912
[TBL] [Abstract][Full Text] [Related]
7. Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies.
MacLean DB; Matsui H; Suri A; Neuwirth R; Colombel M
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1445-53. PubMed ID: 24762108
[TBL] [Abstract][Full Text] [Related]
8. Effects and therapeutic potentials of kisspeptin analogs: regulation of the hypothalamic-pituitary-gonadal axis.
Matsui H; Asami T
Neuroendocrinology; 2014; 99(1):49-60. PubMed ID: 24356680
[TBL] [Abstract][Full Text] [Related]
9. The effects of chronic subcutaneous administration of an investigational kisspeptin analog, TAK-683, on gonadotropin-releasing hormone pulse generator activity in goats.
Yamamura T; Wakabayashi Y; Sakamoto K; Matsui H; Kusaka M; Tanaka T; Ohkura S; Okamura H
Neuroendocrinology; 2014; 100(2-3):250-64. PubMed ID: 25428554
[TBL] [Abstract][Full Text] [Related]
10. Chronic subcutaneous administration of kisspeptin-54 causes testicular degeneration in adult male rats.
Thompson EL; Murphy KG; Patterson M; Bewick GA; Stamp GW; Curtis AE; Cooke JH; Jethwa PH; Todd JF; Ghatei MA; Bloom SR
Am J Physiol Endocrinol Metab; 2006 Nov; 291(5):E1074-82. PubMed ID: 16787965
[TBL] [Abstract][Full Text] [Related]
11. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
12. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion.
Zheng JY; Fulu MY
Int J Pharm; 2006 Jan; 307(2):209-15. PubMed ID: 16300912
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft model.
Kogame A; Ishikawa K; DeJongh J; Tagawa Y; Matsui H; Moriya Y; Kondo T; Asahi S
Biopharm Drug Dispos; 2020 Jul; 41(7):283-294. PubMed ID: 32562504
[TBL] [Abstract][Full Text] [Related]
14. Additive effect of simultaneous continuous administration of degarelix and TAK-448 on LH suppression in a castrated rat model.
Stalewski J; Hargrove DM; Wolfe M; Kohout TA; Kamal A
Eur J Pharmacol; 2018 Apr; 824():24-29. PubMed ID: 29378196
[TBL] [Abstract][Full Text] [Related]
15. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of continuous exposure to the investigational metastin/kisspeptin analog TAK-683 on pulsatile and surge mode secretion of luteinizing hormone in ovariectomized goats.
Tanaka T; Ohkura S; Wakabayashi Y; Kuroiwa T; Nagai K; Endo N; Tanaka A; Matsui H; Kusaka M; Okamura H
J Reprod Dev; 2013 Dec; 59(6):563-8. PubMed ID: 24047956
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men.
Scott G; Ahmad I; Howard K; MacLean D; Oliva C; Warrington S; Wilbraham D; Worthington P
Br J Clin Pharmacol; 2013 Feb; 75(2):381-91. PubMed ID: 22803642
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of testosterone production with ketoconazole alone and in combination with a gonadotropin releasing hormone analogue in the rat.
English HF; Santner SJ; Levine HB; Santen RJ
Cancer Res; 1986 Jan; 46(1):38-42. PubMed ID: 3079588
[TBL] [Abstract][Full Text] [Related]
19. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
20. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
